Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Chemomab Therapeutics Ltd. Sponsored ADR (CMMB : NSDQ)

• Company Description    Chemomab Ltd. is a clinical-stage biotech company. It focuses on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need. The company's product pipeline includes CM-101. Chemomab Ltd., formerly known as Anchiano Therapeutics Ltd., is based in TEL-AVIV, Israel. Number of Employees: 10

• Price / Volume Information    Yesterday's Closing Price: $1.03 Daily Weekly Monthly 20 Day Moving Average: 109,397 shares Shares Outstanding: 7.25 (millions) Market Capitalization: $7.46 (millions) Beta: 0.74 52 Week High: $3.44 52 Week Low: $1.01 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -53.18% -52.69% 12 Week -32.68% -34.32% Year To Date -37.58% -41.53%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 10 HABARZEL STREET BUILDING C 10TH FLOOR - TEL AVIV,L3 6158101 ISR ph: 972-77-331-0156 fax: - ir@chemomab.com http://www.chemomab.com

• General Corporate Information    Officers Adi Mor - Chief Executive Officer; Chief Scientific Officer Nissim Darvish - Chairman Sigal Fattal - Chief Financial Officer Alan Moses - Director Claude Nicaise - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 16385C203 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 10/29/26 Share - Related Items Shares Outstanding: 7.25 Most Recent Split Date: 8.00 (0.25:1) Beta: 0.74 Market Capitalization: $7.46 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 10/29/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.85 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 25.00% vs. Previous Quarter: -22.73% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/26 - - 06/30/26 - -92.14 03/31/26 - -89.03 ROA 09/30/26 - - 06/30/26 - -82.05 03/31/26 - -79.68 Current Ratio 09/30/26 - - 06/30/26 - 6.41 03/31/26 - 10.31 Quick Ratio 09/30/26 - - 06/30/26 - 6.41 03/31/26 - 10.31 Operating Margin 09/30/26 - - 06/30/26 - - 03/31/26 - - Net Margin 09/30/26 - - 06/30/26 - - 03/31/26 - - Pre-Tax Margin 09/30/26 - - 06/30/26 - - 03/31/26 - - Book Value 09/30/26 - - 06/30/26 - 1.21 03/31/26 - 1.49 Inventory Turnover 09/30/26 - - 06/30/26 - - 03/31/26 - - Debt-to-Equity 09/30/26 - - 06/30/26 - 0.00 03/31/26 - 0.00 Debt-to-Capital 09/30/26 - - 06/30/26 - 0.00 03/31/26 - 0.00

Powered by Zacks Investment Research ©